Coronary Artery Restenosis in Women by History of Preeclampsia

Background A history of preeclampsia is associated with increased risk of coronary artery disease and experimental evidence suggests that a history of preeclampsia also increases the risk of restenosis. However, the extent to which a history of preeclampsia is associated with risk of restenosis after percutaneous coronary intervention in women is unknown. Methods and Results We included 6065 parous women aged ≤65 years with first percutaneous coronary intervention on 9452 segments 2006 to 2017, linking nationwide data on percutaneous coronary intervention and delivery history in Sweden. Main outcomes were clinical restenosis and target lesion revascularization within 2 years. We accounted for segment‐, procedure‐, and patient‐related potential predictors of restenosis in proportional hazards regression models. Restenosis occurred in 345 segments (3.7%) and target lesion revascularization was performed on 383 patients (6.3%). A history of preeclampsia was neither significantly associated with risk of restenosis (predictor‐accounted hazard ratio [HR], 0.71 [95% CI, 0.41–1.23]) nor target lesion revascularization (0.74 [95% CI, 0.51–1.07]) compared with a normotensive pregnancy history. When term and preterm preeclampsia were investigated separately, segments in women with a history of term preeclampsia had a lower risk of restenosis (predictor‐accounted HR, 0.45 [95% CI, 0.21–0.94]). A history of preeclampsia was not significantly associated with death by any cause within 2 years of the index procedure (predictor‐accounted HR 1.06, [95% CI, 0.62–1.80]). Conclusions A history of preeclampsia was not associated with increased risk of restenosis but instead some evidence pointed to a decreased risk. To facilitate future studies and allow for replication, concomitant collection of data on pregnancy complication history and percutaneous coronary intervention outcomes in women is warranted.

[1]  J. Ray,et al.  Maternal cardiovascular disease after twin pregnancies complicated by hypertensive disorders of pregnancy: a population-based cohort study , 2021, Canadian Medical Association Journal.

[2]  P. Teirstein,et al.  Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. , 2020, Journal of the American College of Cardiology.

[3]  J. Snowden,et al.  Multi-Fetal Pregnancy, Preeclampsia, and Long-Term Cardiovascular Disease , 2020, Hypertension.

[4]  P. Serruys,et al.  Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. , 2020, Journal of the American College of Cardiology.

[5]  J. Casas,et al.  Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study. , 2019, Circulation.

[6]  G. Burton,et al.  Pre-eclampsia: pathophysiology and clinical implications , 2019, BMJ.

[7]  C. Ballantyne,et al.  The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines , 2019, Current Cardiovascular Risk Reports.

[8]  S. Karumanchi,et al.  Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .

[9]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[10]  L. Buckley,et al.  Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. , 2018, Journal of the American College of Cardiology.

[11]  Thomas M Maddox,et al.  ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, , 2017, Journal of the American College of Cardiology.

[12]  B. Merkely,et al.  Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent , 2017, Disease markers.

[13]  W. Qiu,et al.  Gender Differences in Outcomes and Predictors of All-Cause Mortality After Percutaneous Coronary Intervention (Data from United Kingdom and Sweden). , 2017, The American journal of cardiology.

[14]  Bernardo Cortese,et al.  Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. , 2016, Journal of thoracic disease.

[15]  A. Avogaro,et al.  Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. , 2016, Circulation research.

[16]  A. Jacobs,et al.  Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age , 2016, Circulation. Cardiovascular quality and outcomes.

[17]  G. Booth,et al.  Prognosis after maternal placental events and revascularization: PAMPER study. , 2016, American journal of obstetrics and gynecology.

[18]  S. Salimi,et al.  Vascular endothelial growth factor (VEGF)‐634G/C polymorphism was associated with severe pre‐eclampsia and lower serum VEGF level , 2015, The journal of obstetrics and gynaecology research.

[19]  B. Cohn,et al.  Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. , 2015, Circulation.

[20]  M. Aronovitz,et al.  Exposure to Experimental Preeclampsia in Mice Enhances the Vascular Response to Future Injury , 2015, Hypertension.

[21]  Ruei-Zeng Lin,et al.  Decreased Level of Cord Blood Circulating Endothelial Colony–Forming Cells in Preeclampsia , 2014, Hypertension.

[22]  A. Lovering,et al.  Decreased endothelial progenitor cells in preeclampsia and consequences for developmental programming. , 2014, Hypertension.

[23]  I. Sargent,et al.  IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? , 2014, Placenta.

[24]  E. Omerovic,et al.  Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2012, European heart journal.

[25]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[26]  P. Damman,et al.  1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. , 2011, JACC. Cardiovascular interventions.

[27]  C. Hubel,et al.  Maternal Circulating CD34+VEGFR-2+ and CD133+VEGFR-2 + Progenitor Cells Increase During Normal Pregnancy but Are Reduced in Women With Preeclampsia , 2010, Reproductive Sciences.

[28]  Ole Fröbert,et al.  Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). , 2009, Journal of the American College of Cardiology.

[29]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[30]  B. Källén,et al.  A Quality Study of a Medical Birth Registry , 1990, Scandinavian journal of social medicine.